title: Update on multiple sclerosis treatments.
abstract: Relapsing-remitting multiple sclerosis (RRMS) management has dramatically changed over the past decade. New drugs have arrived on the market, allowing for more individualised treatment selection. However, this diversity has increased the complexity of RRMS patient follow-up. In this review, we provide summarised information about treatment efficacy, potential side-effects, follow-up recommendations, vaccinations, and pregnancy safety issues for all currently available disease modifying therapies and those awaiting approval.
authors.affiliation: Department of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis, Geneva University Hospital and Faculty of Medicine of the University of Geneva, Switzerland.
authors.forename: Claire
authors.initials: C
authors.lastname: Bridel
authors.affiliation: Department of Genetic and Laboratory Medicine, Division of Laboratory Medicine, Geneva University Hospital, Switzerland.
authors.forename: Patrice H
authors.initials: PH
authors.lastname: Lalive
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003437:Crotonates / Q000627:therapeutic use; D000077561:Daclizumab; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D005650:Fumarates / Q000627:therapeutic use; D006801:Humans; D006885:Hydroxybutyrates; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D009570:Nitriles; D011409:Propylene Glycols / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014052:Toluidines / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003437:Crotonates; D005650:Fumarates; D006885:Hydroxybutyrates; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D009570:Nitriles; D011409:Propylene Glycols; D014052:Toluidines; C527525:teriflunomide; D000074323:Alemtuzumab; D016899:Interferon-beta; C533411:ocrelizumab; D000077561:Daclizumab; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine